This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Neumann, F.-J. Articles by Gawaz, M. Search for Related Content PubMed PubMed Citation Articles by Neumann, F.-J. Articles by Gawaz, M.

Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting

^a Medizinische Klinik and Deutsches Herzzentrum, Technische Universität München, Munich, Germany. This study was supported in part by grants from MSD Sharp & Dohme, Haar, Germany, and from Accumetrics, San Diego, California

View larger version (21K): [in a new window]   Figure 1 Time course of the rate of platelet aggregation after stimulation with 4 µmol/liter of iso-TRAP, as assessed by RPFA during and after infusion of abciximab for 12 h (solid circles), tirofiban for 72 h (solid diamonds) or eptifibatide for 72 h (solid triangles). The plot shows the mean value ± SD. From 24 h onwards, the differences between the three agents were statistically significant (p < 0.001).

View larger version (20K): [in a new window]   Figure 2 Scatter plot of the rate of platelet aggregation after a 2-h infusion of abciximab (solid circles), tirofiban (solid diamonds) or eptifibatide (solid triangles), as assessed by rapid platelet-function assay (RPFA) with 4 µmol/liter of iso-thrombin receptor activating peptide or by turbidimetric aggregometry with 20 µmol/liter of adenosine diphosphate. The p values were calculated by one-way analysis of variance.

View larger version (20K): [in a new window]   Figure 3 Time course of the rate of platelet aggregation after stimulation with 20 µmol/liter of adenosine diphosphate, as assessed by turbidimetric aggregometry during and after infusion of abciximab for 12 h (solid circles), tirofiban for 72 h (solid diamonds) or eptifibatide for 72 h (solid triangles). The plot shows the mean value ± SD. From 24 h onwards, the differences between the three agents were statistically significant (p < 0.034).

View larger version (19K): [in a new window]   Figure 4 Time course of the rate of platelet aggregation after stimulation with 50 µmol/liter of thrombin receptor activating peptide, as assessed by turbidimetric aggregometry during and after infusion of abciximab for 12 h (solid circles), tirofiban for 72 h (solid diamonds) or eptifibatide for 72 h (solid triangles). The plot shows the mean value ± SD. At 24, 48 and 72 h, the differences between the three agents were statistically significant (p < 0.002).

View larger version (25K): [in a new window]   Figure 5 Time course of glycoprotein (GP) Ib immunofluorescence of monocytes as a measure of platelet-monocyte binding (left panel), and Mac-1 immunofluorescence of GP Ib-positive monocytes as a measure of Mac-1 expression on monocytes with adherent platelets (right panel) before and during infusion of abciximab (solid circles), tirofiban (solid diamonds) or eptifibatide (solid triangles). The plot shows the mean value ± SD.